Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. The Danish ...

Novo Nordisk has taken another step towards expanding ... Corvidia’s lead drug candidate – interleukin-6 inhibitor ziltivekimab (formerly COR-001) – is being developed as a therapy for ...

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...